ASML stock etches a fresh buy point as it unveils a new innovation lab, and chip partners like Intel and TSMC expand production. Read More...
ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.
Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.
Barrons.com•
Add Comment